

# Fernando Docobo-PÃ©rez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9114806/publications.pdf>

Version: 2024-02-01

53  
papers

1,619  
citations

236833

25  
h-index

302012

39  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2273  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of inorganic phosphate concentrations in <i>in vitro</i> activity of fosfomicin. <i>Clinical Microbiology and Infection</i> , 2022, 28, 302.e1-302.e4.	2.8	1
2	Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 641-645.	1.3	5
3	Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 338-344.	1.3	7
4	Interplay among Different Fosfomicin Resistance Mechanisms in <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
5	Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. <i>Antibiotics</i> , 2021, 10, 348.	1.5	3
6	Synergistic Quinolone Sensitization by Targeting the <i>recA</i> SOS Response Gene and Oxidative Stress. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	8
7	Disbalancing Envelope Stress Responses as a Strategy for Sensitization of <i>Escherichia coli</i> to Antimicrobial Agents. <i>Frontiers in Microbiology</i> , 2021, 12, 653479.	1.5	1
8	Activity of Fosfomicin and Amikacin against Fosfomicin-Heteroresistant <i>Escherichia coli</i> Strains in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	3
9	Amikacin Combined with Fosfomicin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0029321.	1.4	12
10	Detection of Low-Level Fosfomicin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomicin Susceptibility Determination. <i>Antibiotics</i> , 2020, 9, 802.	1.5	7
11	Role of low-level quinolone resistance in generating tolerance in <i>Escherichia coli</i> under therapeutic concentrations of ciprofloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2124-2132.	1.3	9
12	Contribution of hypermutation to fosfomicin heteroresistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2066-2075.	1.3	6
13	Suppression of the SOS response modifies spatiotemporal evolution, post-antibiotic effect, bacterial fitness and biofilm formation in quinolone-resistant <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 66-73.	1.3	17
14	Population pharmacokinetics and pharmacodynamics of fosfomicin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2018, 24, 1177-1183.	2.8	18
15	Urinary Tract Conditions Affect Fosfomicin Activity against <i>Escherichia coli</i> Strains Harboring Chromosomal Mutations Involved in Fosfomicin Uptake. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	22
16	Molecular insights into fosfomicin resistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw573.	1.3	29
17	Role of inoculum and mutant frequency on fosfomicin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. <i>Clinical Microbiology and Infection</i> , 2017, 23, 325-331.	2.8	38
18	Quinolone Resistance Reversion by Targeting the SOS Response. <i>MBio</i> , 2017, 8, .	1.8	54

#	ARTICLE	IF	CITATIONS
19	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2336-2342.	1.4	29
20	Impact of AAC(6â€²)-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3066-3071.	1.3	39
21	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 992-1002.	1.3	37
22	Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5602-5610.	1.4	87
23	Emergence of OXA-72-producing <i>Acinetobacter pittii</i> clinical isolates. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 195-196.	1.1	9
24	Population Pharmacokinetics of Teicoplanin in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6920-6927.	1.4	29
25	Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3203-3215.	1.3	76
26	Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by <i>Escherichia coli</i> with or without the GyrA mutation Ser83Leu. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1609-1615.	1.3	29
27	Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum $\beta$ -Lactamase (ESBL)-Producing and Non-ESBL-Producing <i>Escherichia coli</i> in an Experimental Murine Sepsis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2109-2113.	1.4	51
28	Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1961-1967.	1.3	25
29	Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant <i>Staphylococcus epidermidis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 613-617.	1.4	38
30	Platelet-activating Factor Receptor Initiates Contact of <i>Acinetobacter baumannii</i> Expressing Phosphorylcholine with Host Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 26901-26910.	1.6	53
31	Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 251-254.	1.1	50
32	In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant <i>Acinetobacter baumannii</i> . <i>Clinical Microbiology and Infection</i> , 2012, 18, E1-E4.	2.8	26
33	Pre-clinical studies of a new quinolone (UB-8902) against <i>Acinetobacter baumannii</i> resistant to ciprofloxacin. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 355-359.	1.1	10
34	Attenuated virulence of a slow-growing pandrug-resistant <i>Acinetobacter baumannii</i> is associated with decreased expression of genes encoding the porins CarO and OprD-like. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 548-549.	1.1	31
35	<i>Acinetobacter baumannii</i> -induced lung cell death: Role of inflammation, oxidative stress and cytosolic calcium. <i>Microbial Pathogenesis</i> , 2011, 50, 224-232.	1.3	36
36	Local imipenem activity against <i>Pseudomonas aeruginosa</i> decreases in vivo in the presence of siliconized latex. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 289-291.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant <i>Acinetobacter baumannii</i> strains. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 895-901.	1.3	20
38	Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant <i>Acinetobacter baumannii</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 1391-1398.	1.3	26
39	Vaccination with Outer Membrane Complexes Elicits Rapid Protective Immunity to Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Infection and Immunity</i> , 2011, 79, 518-526.	1.0	116
40	Impaired Virulence and In Vivo Fitness of Colistin-Resistant <i>Acinetobacter baumannii</i> . <i>Journal of Infectious Diseases</i> , 2011, 203, 545-548.	1.9	138
41	Efficacy of tigecycline vs. imipenem in the treatment of experimental <i>Acinetobacter baumannii</i> murine pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 527-531.	1.3	24
42	Comparative assessment of inoculum effects on the antimicrobial activity of amoxicillin-clavulanate and piperacillin-tazobactam with extended-spectrum $\beta$ -lactamase-producing and extended-spectrum $\beta$ -lactamase-non-producing <i>Escherichia coli</i> isolates. <i>Clinical Microbiology and Infection</i> , 2010, 16, 132-136.	2.8	71
43	Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1165-1172.	1.4	109
44	In Vitro Activity and In Vivo Efficacy of Clavulanic Acid against <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4298-4304.	1.4	9
45	Efficacy of amoxicillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of <i>Escherichia coli</i> resistant to cefoxitin. <i>Clinical Microbiology and Infection</i> , 2008, 14, 582-587.	2.8	3
46	Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by <i>Klebsiella pneumoniae</i> deficient in porins, expressing active efflux and producing QnrA1. <i>Clinical Microbiology and Infection</i> , 2008, 14, 691-697.	2.8	33
47	Clinical Relevance and Prevalence of Polymorphisms in CYP3A5 and MDR1 Genes That Encode Tacrolimus Biotransformation Enzymes in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2008, 40, 2949-2951.	0.3	22
48	Molecular Epidemiology of HIV Type 1 in Newly Diagnosed Patients in Southern Spain. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 881-887.	0.5	12
49	Molecular Screening of <i>Bartonella</i> Species in Rodents from South Western Spain. <i>Vector-Borne and Zoonotic Diseases</i> , 2008, 8, 695-700.	0.6	17
50	Genotypic diversity of imipenem resistant isolates of <i>Acinetobacter baumannii</i> in Spain. <i>Journal of Infection</i> , 2007, 55, 260-266.	1.7	16
51	Prevention of rifampicin resistance in <i>Acinetobacter baumannii</i> in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 689-692.	1.3	45
52	Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 95-100.	1.3	50
53	Efficacy of $\beta$ -lactams against experimental pneumococcal endocarditis caused by strains with different susceptibilities to penicillin. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 732-737.	1.3	3